“It’s going to be absolutely massive,” said Stuart Oakley, head of cash currency trading at Nomura in London. “If we get a vaccine, we’re going to see all that pent up demand coming out.”

Of the roughly 45 vaccines undergoing human trials, those from Pfizer and Moderna are seen as possibly winning regulatory approval this year, with AstraZeneca not far behind.

Investors are looking beyond an expected “excitement rally” and at longer-term beneficiaries and short-selling opportunities.

Pfizer’s Covid vaccine prevents 90% of infections in large study

Nov 9, 2020

“Today is a great day for science and humanity,” Albert Bourla, Pfizer’s chairman and chief executive, said.

“We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen,”he said.

Cinven and Singapore’s GIC to acquire specialist insurance broker Miller

Nov 9, 2020

Headquartered in London, it places £2 billion worth of premiums annually.

Founded in 1902, Miller is a leading specialist insurance and (re)insurance broker operating in the UK, Lloyd’s and internationally. It employs more than 640 people through its offices in London, Ipswich, Brussels, Paris, Singapore and Geneva, covering the world’s major insurance hubs.

Top $5 trillion investor group pushes firms to cut out thermal coal

Nov 9, 2020

In a report seen by Reuters ahead of its release on Monday, the alliance said all companies owned by the group needed to develop their own plans to transition away from thermal coal.

“If no long-term carbon footprint reduction can be produced the members will need to escalate and ultimately divest,” Günther Thallinger, Member of the Board of Management, Investment Management, Environmental, Social and Governance (ESG) at Allianz, said.

« Older Entries

Next Entries »

Briefs